Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

XmaI-RRBS on Luminal B breast carcinoma samples taken prior to chemotherapy

ABSTRACT: XmaI-RRBS on Luminal B breast carcinoma samples taken prior to chemotherapy

PROVIDER: PRJNA509934 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8315970.fastq.gz	Fastqsanger.gz
	SRR8315980.fastq.gz	Fastqsanger.gz
	SRR8315990.fastq.gz	Fastqsanger.gz
	SRR8316000.fastq.gz	Fastqsanger.gz
	SRR8316010.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 50

Similar Datasets

XmaI-RRBS on Luminal B breast carcinoma samples taken prior to chemotherapy

Project description:Luminal B breast carcinoma samples were taken prior to chemotherapy in order to identify epigenomic profiles predictive of neoadjuvant chemotherapy efficacy

2020-12-12 | GSE123828 | GEO

XmaI-RRBS on triple negative breast carcinoma samples taken prior to chemotherapy

Project description:XmaI-RRBS on triple negative breast carcinoma samples taken prior to chemotherapy

| PRJNA509628 | ENA

XmaI-RRBS on triple negative breast carcinoma samples taken prior to chemotherapy

Project description:Triple negative breast carcinoma samples were taken prior to chemotherapy in order to identify epigenomic profiles predictive of neoadjuvant chemotherapy efficacy

2020-12-12 | GSE123712 | GEO

Xmal-RRBS on breast carcinoma samples taken before and after neoadjuvant chemotherapy

Project description:Xmal-RRBS on breast carcinoma samples taken before and after neoadjuvant chemotherapy

| PRJNA835856 | ENA

LINE luminal breast cancer Neoadjuvant Chemotherapy Study

Project description:A targeted gene screen of 365 known cancer genes in luminal breast cancer samples pre-chemotherapy and at resection post-chemotherapy to evalaute clonal expansion of chemotherapy cancer cells.

| EGAS00001001223 | EGA

LncRNA expression profile is associated with neoadjuvant chemotherapy resistance in luminal B breast cancer

Project description:Purpose: Identified the expression profile of lncRNAs associated to neoadjuvant chemotherapy response in 47 luminal B tumors of locally advanced breast cancer patients Methods: We implemented the transcriptomic analysis from 47 luminal B breast cancer samples by paired-end RNA-Seq, as a case-control study (responders vs nonresponders group). Differential expression analysis for lncRNA and mRNA were made to identify lncRNA as predictive biomarkers. Results: We identified a signature of lncRNAs associated with nonresponders group. Additionally, we identified the pathways were differentially expressed lncRNA and mRNA are associated in neoadjuvant chemotherapy response. Additionally, we proposed the clinical application of lncRNA GATA3-AS1 as a predictive biomarker to neoadjuvant chemotherapy response in luminal B breast cancer patients detected by RNA-ISH. Conclusion: we propose the clinical utility of lncRNA GATA3-AS1 detected by RNA-ISH to identify luminal B breast cancer patients that will not respond to neoadjuvant chemotherapy.

2024-08-27 | GSE270967 | GEO

Transcription profiling of human ovarian tumors (43) from untreated patients prior to surgery vs. chemotherapy treated prior to surgery

Project description:Gene expression profiles of malignant carcinomas surgically removed from ovarian cancer patients pre-treated with chemotherapy (neo-adjuvant) prior to surgery group into two distinct clusters. One group clusters with carcinomas from patients not pre-treated with chemotherapy prior to surgery (C-L) while the other clusters with non-malignant adenomas (A-L). Although the C-L cluster is preferentially associated with p53 loss-of-function (LOF) mutations, the C-L cluster cancer patients display a more favorable clinical response to chemotherapy as evidenced by enhanced long-term survivorships. Experiment Overall Design: A set of 43 ovarian tumors was obtained from the Ovarian Cancer Institute (Atlanta). Tissue was collected at the time of surgery and preserved in RNAlater (Ambion, Austin, TX) within one minute of collection. Labeled probe was hybridized to the Affymetrix HG-U95Av2 arrays.

2008-11-22 | E-GEOD-7463 | biostudies-arrayexpress

DNA methylation markers panel can improve prediction of response to neoadjuvant chemotherapy in luminal B breast cancer

Project description:Despite the advantages of neoadjuvant chemotherapy (NACT), associated toxicity is a serious complication that renders monitoring of the patients response to NACT highly important. Thus, prediction of tumor response to treatment is imperative to avoid exposure of potential non-responders to deleterious complications. We have performed genome-wide analysis of DNA methylation by XmaI-RRBS and selected CpG dinucleotides differential methylation of which discriminates luminal B breast cancer samples with different sensitivity to NACT. With this data, we have developed multiplex methylation sensitive restriction enzyme PCR (MSRE-PCR) protocol for determining the methylation status of 10 genes (SLC9A3, C1QL2, DPYS, IRF4, ADCY8, KCNQ2, TERT, SYNDIG1, SKOR2 and GRIK1) that distinguish BC samples with different NACT response. Analysis of these 10 markers by MSRE-PCR in biopsy samples allowed us to reveal three top informative combinations of markers, (1) IRF4 and C1QL2; (2) IRF4, C1QL2, and ADCY8; (3) IRF4, C1QL2, and DPYS, with the areas under ROC curves (AUCs) of 0.75, 0.78 and 0.74, respectively. A classifier based on IRF4 and C1QL2 better meets the diagnostic panel simplicity requirements, as it consists of only two markers. Diagnostic accuracy of the panel of these two markers is 0.75, with the sensitivity of 75% and specificity of 75%.

2020-01-25 | GSE144221 | GEO

Xmal-RRBS on breast carcinoma samples taken before and after neoadjuvant chemotherapy

Project description:Determination of genes demonstrating differential methylation of CpG islands in tumor samples before and after treatment for revealing main metabolic, regulatory and biological processes

2023-05-06 | GSE202402 | GEO

LncRNA expression profile is associated with neoadjuvant chemotherapy resistance in luminal B breast cancer

Project description:LncRNA expression profile is associated with neoadjuvant chemotherapy resistance in luminal B breast cancer

| PRJNA1129126 | ENA